High frequency of β-lactam susceptibility in CTX-M-type extended-spectrum-β-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 11, 2010, Pages 2481-2483

  de Oliveira, Katia Ruschel Pilger ^a   de Freitas, Ana Lucia Peixoto ^b   Willers, Denise Maria Cunha ^a   Barth, Afonso Luís ^a,b   Zavascki, Alexandre Prehn ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

E. coli; ESBLs; K. pneumoniae; P. mirabilis

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE CTX M; CEFEPIME; CEFTAZIDIME; EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; EPSILOMETER TEST; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; LETTER; NONHUMAN; PROTEUS MIRABILIS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PROTEUS MIRABILIS;

EID: 77957866989     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq343     Document Type: Letter

References (10)

1. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA, USA, 2009.
3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.
4. Song W, Moland ES, Hanson ND et al. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol 2005; 43: 4891-4.
5. Kim YK, Pai H, Lee HJ et al. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46: 1481-91.
6. Farmer JJ III. Enterobacteriaceae: introduction and identification. In: Murray PR, Baron EJ, Jorgensen JH et al., eds. Manual of Clinical Microbiology, 7th edn. Washington, DC: American Society for Microbiology Press, 2003; 636-53.
7. Paterson DL, Hujer KM, Hujer AM et al. Extended-spectrumβ-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob Agents Chemother 2003; 47: 3554-60.
8. Bin C, Hui W, Renyuan Z et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 2006; 56: 351-7.
9. Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in patients with extended spectrum β-lactamase βESBL) and non-ESBL infections. J Infect 2007; 54: 463-8.
10. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45: 3548-54.